Article
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
British journal of haematology - 1 Jan 2016
Brümmendorf Tim H, Cortes Jorge E, Khoury Hanna J, Kantarjian Hagop M, Kim Dong-Wook, Schafhausen Philippe, Conlan Maureen G, Shapiro Mark, Turnbull Kathleen, Leip Eric, Gambacorti-Passerini Carlo, Lipton Jeff H
Abstract excerpt
The dual SRC/ABL1 tyrosine kinase inhibitor bosutinib is indicated for adults with Ph+ chronic myeloid leukaemia (CML) resistant/intolerant to prior therapy. This analysis of an ongoing phase 1/2 study (NCT00261846) assessed effects of baseline patient characteristics on long-term efficacy and safety of bosutinib 500 mg/day in adults with imatinib (IM)-resistant (IM-R; n = 196)/IM-intolerant (IM-I; n = 90)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.